Trump takes ‘historic’ action to move Pharmaceuticals

Nondon Editor
110

Trump Administration takes historic steps to lower U.S. prescription drug prices.

In an “historic turning point”, the Trump administration has taken bold action to bring America’s pharmaceutical manufacturing back to the U.S. from China and India.

“Seeking to secure the nation’s supply of critical medications, the Trump administration has signed a $354 million contract that would create the nation’s first strategic stockpile of key ingredients needed to make medicines”, NBC News reported.

“The agreement was signed Monday with Phlow Corp., a generic drug maker based in Virginia.”

The Chinese headquarters of AstraZeneca, which has seen strong sales in the country this year.
The Chinese headquarters of AstraZeneca, which has seen strong sales in the country this year.
Credit: AstraZeneca

White House Trade Adviser Peter Navarro, a staunch China hawk who is the mastermind behind President Donald Trump’s trade war with the communist nation, said that the move

“will not only help bring our essential medicines home but actually do so in a way that is cost competitive with the sweatshops and pollution havens of the world.”

Navarro added, “This is an historic turning point in America’s efforts to onshore its pharmaceutical production and supply chains.”

SPONSORED CONTENT

The New York Times reported that the company could see the contract “extended for a total of $812 million over 10 years, making it one of the largest awards in” the history of the Biomedical Advanced Research and Development Authority (BARDA).

more from
donald trump

Dr. Eric Edwards, the chief executive and president of Phlow, said in an interview with The New York Times, “There are not a lot of people wanting to bring back generic medicine manufacturing to the United States that has been lost to India and China over decades.”

“You need someone like the federal government saying this is too important for us not to focus on”, he added.

On its website, Phlow Corp bills itself as an America First company. “The United States’ drug supply chain is broken, becoming dangerously dependent upon Foreign Suppliers for our most essential generic medicines,” the website reads.

China’s pharma and biotech sector is one of the main focuses of President Xi Jinping’s ‘Made in China 2025’ strategy.
China’s pharma and biotech sector is one of the main focuses of President Xi Jinping’s ‘Made in China 2025’ strategy.
Photo Credit: AstraZeneca

“Phlow was formed to manufacture low-cost, high quality, essential generic drugs for the United States.”

Read the full story